All In Biotech

NDA 017560 · Sun Pharm Industries

Bactrim

Sulfamethoxazole, Trimethoprim · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1975

Apr 15, 1975

Approved uses

3

Original approval plus efficacy supplements

Registered trials

235

70 Phase 3, 31 recruiting

FAERS reports

70,110

59,125 serious, 8,738 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 15, 1990 Supplement 39 · Efficacy
  • Feb 23, 1982 Supplement 18 · Efficacy
  • Apr 15, 1975 Original approval · Type 3 - New Dosage Form
2 products under this application
  • BACTRIM · SULFAMETHOXAZOLE 200MG/5ML; TRIMETHOPRIM 40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SUSPENSION, ORAL · Discontinued
  • BACTRIM PEDIATRIC · SULFAMETHOXAZOLE 200MG/5ML; TRIMETHOPRIM 40MG/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SUSPENSION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Sulfamethoxazole" as an intervention, any sponsor and status, largest first.

All 235 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia5,541
  • off label use4,378
  • fatigue4,197
  • diarrhoea4,079
  • rash3,910
  • nausea3,787
  • dyspnoea3,613
  • pain3,410
  • drug ineffective3,258
  • vomiting3,184
  • drug hypersensitivity2,987
  • pneumonia2,728

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004794
2005844
2006907
20071,079
20081,366
20091,512
20101,574
20112,063
20122,088
20131,567
20142,023
20153,264
20163,943
20174,059
20185,403
20196,015
20205,698
20215,120
20224,485
20234,440
20244,849
20254,072
20262,940

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Bactrim (Sulfamethoxazole/Trimethoprim)

2024 spending

$2K

Beneficiaries

18

36 claims

Per beneficiary

$99

$1.17 per unit

View as table
YearSpending
2020$2,067
2021$1,861
2022$0
2023$1,593
2024$1,780

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,025 on PubMed

Sponsor: Sun Pharm Industries · Also marketed as Bactrim Pediatric

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.